Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

NCT ID: NCT01846351

Last Updated: 2013-05-03

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 16 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2010-02-28

Brief Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Detailed Description

Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Conditions

Epiretinal Membrane; Age Related Macular Degeneration

Study Design

• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Significant epiretinal membrane
• Anti-VEGF treatment for age-related macular degeneration

Exclusion Criteria

• Uveitis
• Macular disorders
• Diabetic retinopathy
• Vascular occlusions

• Minimum Eligible Age: 58 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

New England Retina Associates

OTHER

Sponsor Role: lead

Responsible Party

Peter E. Liggett

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nauman A Chaudhry, MD

Role: PRINCIPAL_INVESTIGATOR

New England Retina Associates

Peter E Liggett, MD

Role: STUDY_CHAIR

New England Retina Associates

Other Identifiers

NAC270608

Identifier Type: -

Identifier Source: org_study_id